Virology, pathogenesis, epidemiology and clinical management of HTLV-1 infection. Proceedings of the 30th HTLV European research network (HERN 2023)
Abstract The 30th workshop of the HTLV European Research Network (HERN) was held in Madrid on September 15–16, 2023. Over fifty researchers from Europe and America convened for a two-day conference to update and discuss basic science, epidemiology, clinical management and therapeutics for patients with HTLV-1 infection. Scientific topics addressed included new estimates for HTLV-1 in Europe; impact of antenatal screening on mother-to-child HTLV-1 infections; new insights into the molecular epidemiology of HTLV-1; reports of elite controllers for HTLV-1 infection; role of antiretrovirals as HTLV-1 pre-exposure prophylaxis; and prospects for a HTLV-1 vaccine. The group agreed to submit a formal request to WHO for increasing the global surveillance and awareness of HTLV-1. This viral infection is a potentially life-threatening, neglected condition with neither treatment nor vaccine. At this time, expanding HTLV-1 screening is the most effective way to reduce viral dissemination..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
NeuroImmune Pharmacology and Therapeutics - 3(2024), 1 vom: 11. Jan., Seite 61-69 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de Mendoza, Carmen [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
© 2024 the author(s), published by De Gruyter, Berlin/Boston |
|---|
| doi: |
10.1515/nipt-2023-0025 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
GRUY009486259 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | GRUY009486259 | ||
| 003 | DE-627 | ||
| 005 | 20240326003530.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240326s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/nipt-2023-0025 |2 doi | |
| 035 | |a (DE-627)GRUY009486259 | ||
| 035 | |a (DE-B1597)nipt-2023-0025-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a de Mendoza, Carmen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Virology, pathogenesis, epidemiology and clinical management of HTLV-1 infection. Proceedings of the 30th HTLV European research network (HERN 2023) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2024 the author(s), published by De Gruyter, Berlin/Boston | ||
| 520 | |a Abstract The 30th workshop of the HTLV European Research Network (HERN) was held in Madrid on September 15–16, 2023. Over fifty researchers from Europe and America convened for a two-day conference to update and discuss basic science, epidemiology, clinical management and therapeutics for patients with HTLV-1 infection. Scientific topics addressed included new estimates for HTLV-1 in Europe; impact of antenatal screening on mother-to-child HTLV-1 infections; new insights into the molecular epidemiology of HTLV-1; reports of elite controllers for HTLV-1 infection; role of antiretrovirals as HTLV-1 pre-exposure prophylaxis; and prospects for a HTLV-1 vaccine. The group agreed to submit a formal request to WHO for increasing the global surveillance and awareness of HTLV-1. This viral infection is a potentially life-threatening, neglected condition with neither treatment nor vaccine. At this time, expanding HTLV-1 screening is the most effective way to reduce viral dissemination. | ||
| 700 | 1 | |a Taylor, Graham |4 aut | |
| 700 | 1 | |a Gessain, Antoine |4 aut | |
| 700 | 1 | |a Thoma-Kress, Andrea K. |4 aut | |
| 700 | 1 | |a Bangham, Charles |4 aut | |
| 700 | 1 | |a Vesterbacka, Jan |4 aut | |
| 700 | 1 | |a Accolla, Roberto |4 aut | |
| 700 | 1 | |a Bazarbachi, Ali |4 aut | |
| 700 | 1 | |a van Weyenbergh, Johan |4 aut | |
| 700 | 1 | |a Cook, Lucy |4 aut | |
| 700 | 1 | |a Casseb, Jorge |4 aut | |
| 700 | 1 | |a Ramos, Juan Carlos |4 aut | |
| 700 | 1 | |a Rosadas, Carolina |4 aut | |
| 700 | 1 | |a Macchi, Beatrice |4 aut | |
| 700 | 1 | |a Cassar, Olivier |4 aut | |
| 700 | 1 | |a Soriano, Vicente |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t NeuroImmune Pharmacology and Therapeutics |d De Gruyter, 2022 |g 3(2024), 1 vom: 11. Jan., Seite 61-69 |h Online-Ressource |w (DE-627)GRUY008709688 |w (DE-600)3107864-3 |x 2750-6665 |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2024 |g number:1 |g day:11 |g month:01 |g pages:61-69 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1515/nipt-2023-0025 |z kostenfrei |3 Volltext |
| 912 | |a GBV_GRUY | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2024 |e 1 |b 11 |c 01 |h 61-69 | ||